Clinical trials: Pulmonary Embolism (PE)
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT)
Evaluation of Soluble Fibrin in Thrombosis Exclusion
The purpose of the study is to evaluate the performances of Soluble Fibrin assay for exclusion of Pulmonary Embolism and Deep Venous Thrombosis.
- Trial name
- FSET (NCT02523937)
- Testing
- Soluble Fibrin
- Where
- France
- Volunteers
- 863 people
- Sponsor
- Diagnostica Stago R&D
Pulmonary Embolism, Chronic Obstructive Pulmonary Disease
Pulmonary Embolism as a Cause of COPD Exacerbations
The primary objective is to demonstrate the clinical benefits of an active strategy for the diagnosis and treatment of PE compared to usual care in patients with unexplained exacerbations of COPD who require hospital admission.
- Trial name
- SLICE (NCT02238639)
- Testing
- Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).
- Where
- 19 sites in Spain
- Volunteers
- 746 people
- Sponsor
- Ministry of Health, Spain
Pulmonary Embolism
Diclofenac for Submassive PE
The primary objective is to demonstrate the clinical benefits of diclofenac (added to standard anticoagulant therapy) over placebo in normotensive patients with acute symptomatic pulmonary embolism and right ventricular…
- Trial name
- AINEP-1 (NCT01590342)
- Testing
- Diclofenac
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Ministry of Health, Spain
Pulmonary Embolism
Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux
To assess the safety and efficacy of outpatient treatment using fondaparinux and oral Vit K antagonist, warfarin (Coumadin) in patients with stable acute pulmonary embolus (APE)when initial therapy is administered in the…
- Trial name
- NCT00378027
- Testing
- Fondaparinux
- Where
- United States
- Sponsor
- The Cleveland Clinic
Venous Thromboembolism
Follow-up in Rivaroxaban Patients in Setting of Thromboembolism
In patients with acute clots (deep vein thrombosis or pulmonary embolism) the investigators will collect real world data on their short and long term outcomes.
- Trial name
- FIRST (NCT02248610)
- Testing
- Non-interventional study
- Where
- 4 sites in United Kingdom
- Volunteers
- 1,343 people
- Sponsor
- King's College Hospital NHS Trust
Venous Thromboembolism, Pulmonary Embolism
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening.
- Trial name
- PHACS (NCT00876915)
- Testing
- dalteparin injection
- Where
- 7 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- University of Rochester
Pulmonary Embolism Acute
Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)
This study is a prospective, single-arm, interventional, multicenter study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary…
- Trial name
- NCT06672510
- Testing
- ATC
- Where
- 7 sites in United States
- Volunteers
- 118 people
- Sponsor
- Akura Medical
Syncope
Prevalence of PE in ED Patients With Isolated Syncope
Syncope is a rapid onset, transient, loss of consciousness with a short duration. This symptom has been reported to be a specific presentation of patients with pulmonary embolism.
- Trial name
- PEEPS (NCT03487237)
- Testing
- Ddimer testing
- Where
- France
- Volunteers
- 459 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Dyspnea, Pulmonary Embolism
Inhaled Nitric Oxide (iNO) in Post-Pulmonary Embolism (Post-PE)
Following acute pulmonary embolism (PE), up to a third of patients develop post-PE syndrome described as having persistent breathlessness (dyspnea), impaired exercise capacity, and a reduced quality of life.
- Trial name
- NCT04920695
- Testing
- Nitric Oxide
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Dr. Denis O'Donnell
Pulmonary Embolism (Diagnosis)
Adjust-Unlikely PE
The aim of this pilot study is to assess the feasibility of a larger study to determine the Adjust-Unlikely algorithm safety and efficiency for diagnosing PE. The pilot study objectives are to: 1.
- Trial name
- NCT05708794
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Dr. Kerstin de Wit
Acute Pulmonary Embolism
Pilot Study to Evaluate the Role of EBUS in the Diagnosis of Acute PE in Critically Ill Patients
Acute pulmonary embolism (PE) in critically ill patients is common and often life threatening. The diagnosis of acute PE is often entertained in intensive care unit patients who develop unexplained hypotension or hypoxemia.
- Trial name
- VEBUS (NCT04047784)
- Testing
- Endobronchial ultrasound (EBUS)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles
Pulmonary Embolism, Venous Thrombosis
XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
The trial is an open-label, randomized, trial examining novel biomarkers of thrombosis in patients managed with rivaroxaban vs. standard care following treatment of pulmonary embolism (PE) with catheter-guided alteplase.
- Trial name
- XENITH (NCT02506985)
- Testing
- rivaroxaban, warfarin
- Volunteers
- 10 people
- Sponsor
- Susan Smyth
Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute
Repeated Examinations for Typing Pulmonary Embolism
PURPOSE The two related purposes of the RE-TyPE study are: 1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and 2.
- Conditions
- Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute, Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism With Right Ventricle Enlargement
- Trial name
- RE-TyPE (NCT07491094)
- Where
- 3 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Thrombolytic Therapy, Thrombolysis
Submassive Pulmonary Embolism Experience With EKOS
This single site study evaluates the efficacy of ultrasound accelerated thrombolysis using EKOS Endovascular Device with a standard infusion of thrombolytics for treatment of PE
- Conditions
- Thrombolytic Therapy, Thrombolysis, Mechanical Thrombolysis, Pulmonary Embolism
- Trial name
- SPEEK (NCT02926742)
- Testing
- EkoSonic Endovascular System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Krishna Mannava, MD, FACS, RPVI
Pulmonary Embolism, Pulmonary Hypertension
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
To determine whether peripheral low dose systemic thrombolysis (PLST) is non-inferior to catheter directed acoustic pulse thrombolysis (ACDT) in improving RV function and reducing pulmonary artery pressures in submassive…
- Conditions
- Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
- Trial name
- NCT03581877
- Testing
- Alteplase, EKOS
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwell Health
Pulmonary Embolism, Atrial Fibrillation
Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
This is a multi-center study designed to evaluate the accuracy and precision of the INRatio® Prothrombin Time (PT) Monitoring System, utilizing the INRatio test strip newly designed for low sample volume and heparin…
- Conditions
- Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis
- Trial name
- ECLIPSE-01 (NCT01037270)
- Where
- 4 sites in United States
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Abbott RDx Cardiometabolic
Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 4 (NCT00362232)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 124 sites in United States, Bulgaria and 11 more
- Volunteers
- 3,148 people
- Sponsor
- Bayer
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
This is a pilot study of the Flow Medical Catheter, a catheter-based device used to deliver clot-dissolving medication directly to a blood clot in the lungs (pulmonary embolism).
- Trial name
- PE (NCT07681154)
- Testing
- Thrombolysis Catheter
- Volunteers
- 20 people
- Sponsor
- Flow Medical Solutions, Inc.
Venous Thromboembolic Disease, Deep Venous Thrombosis
Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry
Venous thromboembolic disease is a significant cause of morbidity and mortality. The purpose of the RAPID registry is to collect information on the Angiovac procedure and Angiovac device used in the treatment of deep venous…
- Conditions
- Venous Thromboembolic Disease, Deep Venous Thrombosis, Right Heart Pathology, Pulmonary Embolism
- Trial name
- RAPID (NCT04414332)
- Testing
- Data collection only
- Volunteers
- 234 people
- Sponsor
- University of California, Los Angeles
Deep Vein Thrombosis, Fibrillation, Atrial
Odiparcil For The Prevention Of Venous Thromboembolism
Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
- Conditions
- Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- NCT00244725
- Testing
- Odiparcil, Warfarin, Coumadin
- Where
- 101 sites in United States, Australia and 11 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline